Related Experiment Video
Updated: Jul 26, 2026
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Targeted beta-globin gene conversion in human hematopoietic CD34(+ )and Lin(-)CD38(-)cells
1Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Gene Therapy
|February 22, 2002
Summary
Chimeric oligonucleotides can correct sickle cell anemia mutations in primitive human blood cells. This gene conversion in CD34(+) and Lin(-)CD38(-) cells shows therapeutic potential for sickle cell disease patients.
Area of Science:
- Molecular Biology
- Hematology
- Gene Therapy
Background:
- Chimeric oligonucleotides effectively correct mutations in various models.
- Application in primitive human blood cells remains challenging.
- Sickle cell anemia is caused by a specific mutation in the beta-globin gene.
Purpose of the Study:
- To assess the efficacy of chimeric oligonucleotides in correcting the sickle cell anemia mutation in human hematopoietic stem cells.
- To evaluate gene conversion rates in CD34(+) and Lin(-)CD38(-) cells.
- To determine the potential therapeutic benefit for sickle cell disease.
Main Methods:
- Chimeric oligonucleotides targeting the A to T substitution in the beta-globin gene were designed.
- Microinjection was used to introduce oligonucleotides into normal human CD34(+) and Lin(-)CD38(-) cells.
- Gene conversion was analyzed in cultured cell progeny using allele-specific PCR and sequence analysis.
Main Results:
- Gene conversion was detected in 23% of experimental samples from microinjected CD34(+) and Lin(-)CD38(-) cells after 4 weeks of culture.
- Gene conversion was confirmed at the mRNA level in erythroid progeny of Lin(-)CD38(-) cells.
- Conversion rates of 10-15% were achieved in 11% of samples, confirmed by PCR and sequencing.
Conclusions:
- Chimeric oligonucleotides can achieve gene conversion in primitive human hematopoietic stem cells.
- The achieved conversion rates hold potential therapeutic promise for sickle cell disease.
- Further research may lead to effective gene therapy strategies for sickle cell anemia.
